# Suraksha Diagnostic (NSE: SURAKSHA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SURAKSHA · Pivot · prices to 22 Oct 2026

Suraksha Diagnostic (NSE: SURAKSHA) closed at ₹294.05 on 22 Oct 2026, up 1.75% on the day. With a market capitalisation of ₹1,531 Cr, it ranks 1264th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

At its last close the stock traded at 47.6× trailing earnings, against a return on equity of 13.1% in FY26. Over the past year the share price has risen 1.1%. Its 52-week range is ₹224.10 (30 Mar 2026) to ₹360.00 (21 Sep 2026); the last close is 18.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹81 Cr (+25.1% year on year) and net profit ₹6 Cr (−14.1%), on a consolidated basis. Promoters held 49.10% of the company as of 30 Jun 2026; 0.10% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹294.05 |
| Market cap | ₹1,531 Cr |
| P/E (trailing) | 47.6 |
| ROE | 13.1% (FY26) |
| ROCE | 14.7% (FY26) |
| Debt to equity | 0.01 |
| 52-week high | ₹360.00 (21 Sep 2026) |
| 52-week low | ₹224.10 (30 Mar 2026) |
| 1-year return | +1.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹81 Cr | +25.1% | ₹6 Cr | −14.1% | ₹1.21 |
| Q3 FY26 | ₹78 Cr | +30.5% | ₹7 Cr | +21.1% | ₹1.44 |
| Q2 FY26 | ₹79 Cr | +17.9% | ₹9 Cr | −13.1% | ₹1.73 |
| Q1 FY26 | ₹73 Cr | +19.5% | ₹9 Cr | +19.7% | ₹1.80 |
| Q4 FY25 | ₹65 Cr | +17.9% | ₹7 Cr | +13.4% | ₹1.42 |
| Q3 FY25 | ₹60 Cr | +14.8% | ₹6 Cr | +31.7% | ₹1.18 |
| Q2 FY25 | ₹67 Cr | +11.2% | ₹10 Cr | +21.8% | ₹1.94 |
| Q1 FY25 | ₹61 Cr | +17.6% | ₹8 Cr | +95.2% | ₹1.49 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹252 Cr | ₹31 Cr |
| FY24 | ₹219 Cr | ₹23 Cr |
| FY23 | ₹190 Cr | ₹6 Cr |
| FY22 | ₹223 Cr | ₹21 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 49.10%
- Foreign institutions: 13.47%
- Domestic institutions: 23.23%
- Non-institutions: 14.21%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Jupiter Life Line Hospitals](https://app.pivotnow.in/stock/JLHL) | ₹244.75 | ₹1,605 Cr | 8.3 | — |
| [Astec LifeSciences](https://app.pivotnow.in/stock/ASTEC) | ₹700.20 | ₹1,560 Cr | — | — |
| [Gujarat Kidney And Super Speciality](https://app.pivotnow.in/stock/GKSL) | ₹183.00 | ₹1,443 Cr | 73.5 | — |
| [Amrutanjan Health Care](https://app.pivotnow.in/stock/AMRUTANJAN) | ₹496.20 | ₹1,435 Cr | 24.8 | — |
| [Jagsonpal Ser](https://app.pivotnow.in/stock/JAGSNPHARM) | ₹216.03 | ₹1,422 Cr | 34.2 | — |
| [TTK Healthcare](https://app.pivotnow.in/stock/TTKHLTCARE) | ₹994.70 | ₹1,406 Cr | 21.4 | — |

## Questions and answers

### What is the share price of Suraksha Diagnostic today?

Suraksha Diagnostic (NSE: SURAKSHA) last closed at ₹294.05 on 22 Oct 2026. Its 52-week high is ₹360.00 and its 52-week low is ₹224.10.

### What is the market cap of Suraksha Diagnostic?

Suraksha Diagnostic's market capitalisation is ₹1,531 Cr (₹1,531 Cr) at the 22 Oct 2026 close, ranking 1264th among the NSE companies Pivot tracks.

### What is the P/E ratio of Suraksha Diagnostic?

Suraksha Diagnostic trades at a trailing P/E of 47.6. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 24.8.

### What is the ROE and ROCE of Suraksha Diagnostic?

Return on equity was 13.1% in FY26 and return on capital employed was 14.7% in FY26 (consolidated figures).

### Is Suraksha Diagnostic a debt-free company?

Suraksha Diagnostic is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.

### What were Suraksha Diagnostic's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Suraksha Diagnostic reported revenue of ₹81 Cr, +25.1% year on year, and net profit of ₹6 Cr, −14.1% year on year.

### How has Suraksha Diagnostic stock performed over the last year?

Suraksha Diagnostic's share price has risen 1.1% over the past year, +12.6% over three months and −15.7% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Suraksha Diagnostic?

As of 30 Jun 2026: promoters 49.10%, foreign institutions 13.47%, domestic institutions 23.23%, non-institutions 14.21%. 0.10% of promoter shares were pledged.

### Who are Suraksha Diagnostic's competitors?

The listed Pharma & Healthcare companies closest to Suraksha Diagnostic by market cap are Jupiter Life Line Hospitals, Astec LifeSciences, Gujarat Kidney And Super Speciality, Amrutanjan Health Care, Jagsonpal Ser and TTK Healthcare.

### Is Suraksha Diagnostic a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Suraksha Diagnostic's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SURAKSHA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.